U.S. Clinical Trial of MicroVention’s New Dual-Layer Stent For Cerebral Aneurysm Flow Diversion

Terumo subsidiary, MicroVention, Inc., has successfully completed its first enrollment in a multi-center, prospective, pivotal U.S. clinical trial to demonstrate the safety and efficacy of its FRED™ flow diversion system for treating intracranial aneurysms.

MicroVention Announces First Trial Enrollment In Their U.S. Clinical Trial Of Its New Dual-Layer Stent For Cerebral Aneurysm Flow Diversion (via PR Newswire)

TUSTIN, Calif., July 22, 2013 /PRNewswire/ — MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced earlier last week that they successfully completed their first enrollment in a multi-center, prospective, pivotal U.S. clinical…

published: July 23, 2013 in: Clinical Studies/Trials, Neuro

Most read

Latest

^